Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantheus HoldingsLNTH -0.99%80 EV-to-EBITDA is 14.04 as of Jul. 31, 2026, which is 5% above its 10-year median of 13.38. GuruFocus rates LNTH with a GF Score™ of 80/100 and a GF Value™ of $90.50 (Fairly Valued). The stock has 4 warning signs investors should review. Among 747 Drug Manufacturers companies, Lantheus Holdings ranks worse than 54.08% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lantheus Holdings's enterprise value is $6,638 Mil.
Lantheus Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $473 Mil. Therefore, Lantheus Holdings's EV-to-EBITDA for today is 14.04.
The historical rank and industry rank for Lantheus Holdings's EV-to-EBITDA or its related term are showing as below:
LNTH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -152.62 Med: 13.38 Max: 358.64
Current: 14.04
During the past 13 years, the highest EV-to-EBITDA of Lantheus Holdings was 358.64. The lowest was -152.62. And the median was 13.38.
LNTH's EV-to-EBITDA is ranked worse than 54.08% of 747
companies
in the Drug Manufacturers industry
Industry Median: 12.88
vs LNTH: 14.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lantheus Holdings's PE Ratio (TTM) for today is calculated as:
Lantheus Holdings's share price for today is $100.00.
Lantheus Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Lantheus Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's EV-to-EBITDA falls into.
Lantheus Holdings's current Enterprise Value is $6,638 Mil.
Lantheus Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $473 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a EV-to-EBITDA of 14.04 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lantheus Holdings. This is near median its historical median of 13.38. According to the industry distribution chart, Lantheus Holdings ranks #404 out of 747 companies in the Drug Manufacturers industry, placing it in the top 54.1%.
Is Lantheus Holdings' EV-to-EBITDA too high?
Lantheus Holdings' current EV-to-EBITDA of 14.04 is near median its 10-year median of 13.38. The Drug Manufacturers industry median EV-to-EBITDA is 12.88. Lantheus Holdings' value of 14.04 is 9% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #404 out of 747 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' EV-to-EBITDA compare to HIMS and LQDA?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #404 out of 747 companies for EV-to-EBITDA. This places Lantheus Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 12.88. Lantheus Holdings' value of 14.04 is 9% above this benchmark. While the company's 10-year median is 13.38 vs. the industry median of 12.88, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.88, based on 747 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current EV-to-EBITDA of 14.04 is 9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lantheus Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current EV-to-EBITDA is 14.04, which is near median its own 10-year median of 13.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Fairly Valued. The stock's GF Value™ is $90.50, compared to a current price of $100.00 — trading 10.5% above its estimated fair value. The current EV-to-EBITDA is 14.04, which is near median its 10-year median of 13.38 and 9% above the Drug Manufacturers industry median of 12.88. Lantheus Holdings' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current EV-to-EBITDA is 14.04 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $100.00 is trading 10.5% above its estimated GF Value™ of $90.50.
GuruFocus considers Lantheus Holdings to be Fairly Valued.
Key valuation signals for LNTH:
EV-to-EBITDA: 14.04 (near median its 10-year median of 13.38)
GF Value™: $90.50 vs. price of $100.00 (10.5% above fair value)
Industry Position: 9% above the Drug Manufacturers median (#404 of 747)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
80GF Score
Get the complete analysis for LNTH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
